Allianz's Analyst Likes Biogen, Celgene & Gilead

John Schroer of Allianz Global Investors

. He said that his first pick would be

, which is a leading company in the multiple sclerosis space. He thinks that the company will have 20 to 25 percent earnings growth over the next three years and it has a valuation of 25 times earnings. The biotech stock sold off on Friday on the news about potential pricing pressure on

hepatitis C medicine. Schroer thinks that

is a great stock, trading at 11 times earnings, with a strong growth potential that could easily trade at $200 billion market capitalization.

has also found its place on the list of stocks in the biotech space that John Schroer would buy.

fell 0.15% on Friday and it closed at $93.79.